Oral spray device testing shows how the pump, actuator, nozzle, formulation, dose volume, and user interface affect measurable spray performance. When no single oral spray standard governs the product, concepts from USP <601>, ISO 13320, and FDA nasal / inhalation spray guidance can help frame droplet size, spray geometry, emitted dose, and use-condition collection. Testing can support decisions when:
- PSD testing compares oral spray formulations, pumps, and nozzles using ISO 13320 laser diffraction or aerodynamic sizing when respirable aerosol is a concern.
- Spray pattern and plume geometry document actuator, nozzle, or viscosity changes for FDA comparability and product-quality documentation.
- Dose uniformity and emitted dose studies quantify actuation-to-actuation output, priming state, and orientation effects under USP <601> concepts.
- Breathing simulation evaluates mouthpiece geometry, inhalation timing, and oral fixture collection using USP <601> and FDA use-condition framing.
- Stability pulls track PSD, plume, emitted dose, clogging, and residue effects after ICH Q1A storage or product-specific aging conditions.
Use oral spray testing when droplet size, plume direction, dose consistency, or user coordination may affect the material delivered. Before samples arrive, a defined protocol establishes the actuation sequence, oral-interface geometry, collection endpoint, assay plan, and acceptance logic.